[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529144":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":22,"locations":30,"responsibleParty":49,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants receiving neoadjuvant nivolumab in combination with platinum-based chemotherapy",null,[12],"Drug: Neoadjuvant nivolumab in combination with platinum-based chemotherapy",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Neoadjuvant nivolumab in combination with platinum-based chemotherapy","Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics",[9],[20],{"name":5,"affiliation":5,"role":21},"STUDY_DIRECTOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Klinikverbund Allgaeu","RECRUITING","Kempten (Allgäu)","Bavaria","87439","Germany","DE",{"type":40,"coordinates":41},"Point",[42,43],10.31389,47.72674,{"lat":43,"lon":42},[46],{"name":47,"role":25,"phone":48,"phoneExt":10,"email":10},"Christian Schumann, Site 0001","+8315302382",{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100529144","an-observational-study-to-evaluate-neoadjuvant-nivolumab-opdivo-in-combination-with-platinum-based-chemotherapy-in-non-metastatic-non-small-cell-lung-cancer-participants-in-germany-100529144",false,"NCT06169956","An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany","Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy for Non-Metastatic NSCLC: A German, Nationwide, Prospective, Observational, Multicenter Study in Patients Scheduled to Receive 3 Cycles Nivolumab in Combination With Platinum-Based Chemotherapy for Non-Metastatic (Stage and PD-L1 Expression According to Label) Non-Small Cell Lung Cancer","NENI","Inclusion Criteria:\n\n* Aged 18 years or older\n* Diagnosis of non-metastatic non-small cell lung cancer with tumor Programmed death-ligand 1 (PD-L1) expression level of 1% or more (tumor proportion score (TPS); according to label approved in the European Union)\n* Decision to initiate a neoadjuvant treatment with nivolumab plus platinum-based chemotherapy for treatment of non-small cell lung cancer according to current Summary of product characteristics and independent of the study\n* Willing to complete patient-reported outcome questionnaires and sufficient understanding of the German language\n* Signed written informed consent\n* Other criteria according to current Summary of product characteristics\n\nExclusion Criteria:\n\n* Current primary diagnosis of cancer other than non-small cell lung cancer that requires systemic or other treatment\n* Other contraindications according to current Summary of product characteristics","ALL","18 Years",{"count":62,"type":63},400,"ESTIMATED","OBSERVATIONAL","The purpose of this observational study is to collect and evaluate real-world data to assess the effectiveness of neoadjuvant nivolumab when given in combination with platinum-based chemotherapy in participants with early-stage, resectable non-small cell lung cancer (NSCLC) in Germany",[67],"Resectable Non-small Cell Lung Cancer","2024-04-17",{"date":70,"type":71},"2024-04-18","ACTUAL",{"date":73,"type":71},"2023-11-30",{"date":75,"type":63},"2030-09-30",{"name":5,"class":6},1]